AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1069608
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of daunorubicin, cytosine arabinoside, 6-thioguanine, and pyrimethamine
Trial: 31221165
Drug: Multi-arm trial
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-arm trial designs with varying antibiotic treatment durations
Trial: 28094141
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg intravenous zanamivir
Trial: 28094141
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg intravenous zanamivir
Trial: 28094141
Drug: Oseltamivir (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (75 mg oral, twice a day)
Trial: 21525686
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 2% lidocaine HCl with 1:80,000 epinephrine injected into the buccal vestibule
Trial: 17138173
Drug: Palatal injection
RxNorm normalized name: malate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palatal injection
Trial: 9101374
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen (0.05 mg/day 17 beta‐estradiol) and calcium
Trial: 9101374
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen in high bone turnover (HT) patients
Trial: 9101374
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen in low bone turnover (LT) patients
Trial: 1529687
Drug: Insulin‐like Growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin‐like Growth Factor I (IGF I) plasma levels in children with Perthes' disease
Trial: 1529687
Drug: Insulin‐like Growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin‐like Growth Factor I (IGF I) plasma levels in matched controls
Trial: 29099960
Drug: PNCA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNCA with a basal infusion
Trial: 29099960
Drug: PNCA without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PNCA without a basal infusion
Trial: 29099960
Drug: PNCA (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNCA (both with and without basal infusion)
Trial: 11583720
Drug: colesevelam 3.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colesevelam 3.8 g/day
Trial: 19508464
Drug: atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin 10 mg/day
Trial: 11583720
Drug: coadministered colesevelam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: coadministered colesevelam 3.8 g/day plus atorvastatin 10 mg/day
Trial: 18809153
Drug: atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin 80 mg/day
Trial: 8018463
Drug: Nadroparin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (0.4 ml)
Trial: 8018463
Drug: Enoxaparin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (0.4 ml)
Trial: 31865604
Drug: 2 consecutive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 consecutive daily fractions of 5-6 Gy
Trial: 24920349
Drug: Levosimendan (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.2 µg/kg/min) administered for 6 h at 2-week intervals over 6 weeks
Trial: 24920349
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 6 h at 2-week intervals over 6 weeks
Trial: 22746016
Drug: L group
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L group (Landiolol)
Trial: 16222918
Drug: Prenatal multiple
RxNorm normalized name: Ascorbic Acid/Biotin/Calcium/Cholecalciferol/Chromium/Copper/Cyanocobalamin/Docosahexaenoic Acid/Eicosapentaenoic Acid/Fish Oil/Folic Acid/Iodine/Iron/Magnesium/Manganese/Niacin/Pantothenic Acid/Phytonadione/Pyridoxine/Riboflavin/Selenium/Thiamine/Vitamin A/Vitamin E/Zinc 150 MG-150 MCG-50 MG-800 IU-60 MCG-1 MG-16 MCG-250 MG-50 MG-500 MG-400 MCG-75 MCG-13.5 MG-50 MG-1 MG-40 MG-20 MG-100 MCG-5 MG-4 MG-35 MCG-3.4 MG-4000 IU-75 IU-7.5 MG Oral Capsule, Liquid Filled [CARLSON PRENATAL MULTIPLE WITH DHA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal multiple micronutrient supplements (MM), 6 days per week from early pregnancy to delivery.
Trial: 16222918
Drug: Iron only
RxNorm normalized name: Iron only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron only (FE) supplements, 6 days per week from early pregnancy to delivery.
Trial: 16222918
Drug: Prenatal multiple
RxNorm normalized name: Ascorbic Acid/Biotin/Calcium/Cholecalciferol/Chromium/Copper/Cyanocobalamin/Docosahexaenoic Acid/Eicosapentaenoic Acid/Fish Oil/Folic Acid/Iodine/Iron/Magnesium/Manganese/Niacin/Pantothenic Acid/Phytonadione/Pyridoxine/Riboflavin/Selenium/Thiamine/Vitamin A/Vitamin E/Zinc 150 MG-150 MCG-50 MG-800 IU-60 MCG-1 MG-16 MCG-250 MG-50 MG-500 MG-400 MCG-75 MCG-13.5 MG-50 MG-1 MG-40 MG-20 MG-100 MCG-5 MG-4 MG-35 MCG-3.4 MG-4000 IU-75 IU-7.5 MG Oral Capsule, Liquid Filled [CARLSON PRENATAL MULTIPLE WITH DHA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal multiple micronutrient supplements (MM) among overweight women.
Trial: 16222918
Drug: Iron only
RxNorm normalized name: Iron only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron only (FE) supplements among non-overweight women.
Trial: 10510142
Drug: Chlorpromazine 50
RxNorm normalized name: chlorpromazine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine 50 mg
Trial: 10831016
Drug: Risperidone 2
RxNorm normalized name: risperidone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 2 mg
Trial: 8595789
Drug: Tiagabine (TGB)
DrugBank: Tiagabine (DB00906)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiagabine (TGB) hydrochloride monotherapy
Trial: 8595789
Drug: Tiagabine (TGB)
DrugBank: Tiagabine (DB00906)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiagabine (TGB) hydrochloride monotherapy (high-dose)
Trial: 1720407
Drug: Preinduction regimen
RxNorm normalized name: Anacin Aspirin Regimen Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preinduction regimen with low-dose methotrexate followed by CHOP-Bleo chemotherapy
Trial: 1720407
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy with CHOP-Bleo
Trial: 31408870
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (Sufi music at low tempo)
Trial: 16825847
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no music therapy)
Trial: 25539931
Drug: Midluteal (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midluteal (ML) phase after total sleep deprivation (TSD)
Trial: 24166760
Drug: MC4‐NN2‐0453 (0.03-1.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MC4‐NN2‐0453 (0.03-1.50 mg/kg single dose)
Trial: 24166760
Drug: MC4‐NN2‐0453 (0.75-3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MC4‐NN2‐0453 (0.75-3.0 mg/day multiple doses)
Trial: 12140141
Drug: Vinorelbine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m² intravenous bolus on days 1 and 8 plus cisplatin 100 mg/m² on day 1 every 4 weeks (VC)
Trial: 12140141
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C 8 mg/m² i.v. on day 1, vindesine 3 mg/m² i.v. on days 1, 8, 15 and 22, plus cisplatin 100 mg/m² on day 1 every 4 weeks (MVP)
Trial: 7796569
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 600 mg for 1 year
Trial: 2082305
Drug: ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketorolac tromethamine 10 mg 4 times a day as needed
Trial: 2082305
Drug: aspirin 650
RxNorm normalized name: aspirin 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin 650 mg 4 times a day as needed
Trial: 17473118
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of ACP-103 (20-300 mg)
Trial: 17473118
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of ACP-103 (50-150 mg)
Trial: 17473118
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of ACP-103 (up to 300 mg)
Trial: 17473118
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of ACP-103 (up to 100 mg once daily for 14 days)
Trial: 8237845
Drug: Formula supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula supplemented with taurine (479 mumol/L)
Trial: 31666076
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment arms (including Revefenacin and Tiotropium)
Trial: 8109937
Drug: Teicoplanin (T)
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (T) systemic prophylaxis - 800 mg in 100 ml saline as a 5-min infusion 2.5 h before surgery
Trial: 8109937
Drug: Teicoplanin (T)
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (T) regional prophylaxis - 400 mg in 100 ml saline as a 5-min infusion immediately after tourniquet inflation
Trial: 25070100
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg once daily for 6 days
Trial: 25070100
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg once daily for 7 days
Trial: 15867643
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline spray
Trial: 15867643
Drug: 3.0% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0% saline spray
Trial: 12532101
Drug: Omalizumab (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (at least 0.016 mg/kg/IgE [IU/mL], administered subcutaneously every 4 weeks)
Trial: 9895077
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine hydrochloride 0.01% administered via IV regional anesthesia (IVRA)
Trial: 8892538
Drug: Slosson Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slosson Oral Reading Test‐Revised
Trial: 26743526
Drug: 200 μg selenium
RxNorm normalized name: SELENIUM 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg selenium supplements (n=30)
Trial: 25140995
Drug: Methimazole treatment
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole treatment (30 mg daily for at least 1 month, followed by titration)
Trial: 25140995
Drug: Methimazole treatment
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole treatment with L-thyroxine (30 mg daily for at least 1 month, followed by titration with L-thyroxine)
Trial: 21809168
Drug: RLAI (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLAI (25-50 mg i.m. every 2 weeks)
Trial: 12616822
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 150 mg kg‐1 bolus followed by continuous infusion of 12 mg kg‐1 h‐1
Trial: 7934757
Drug: Physically active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physically active commuting to work (PACW) 1 h daily for 10 weeks
Trial: 31666039
Drug: Vaccine reminder
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine reminder and tracker bracelets (two types of silicone bracelets)
Trial: 16839780
Drug: Cortisol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (30 mg)
Trial: 12736018
Drug: 22 mL
RxNorm normalized name: ethanol 0.722 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 mL of a 1% lidocaine solution injected into the neurovascular bundles, the genitourinary diaphragm, and between the rectal wall and prostate
Trial: 12736018
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 2% intrarectal lidocaine jelly
Trial: 11068978
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) plus routine care (RC)
Trial: 8839196
Drug: Pamidronate 100
RxNorm normalized name: pamidronate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 100 mg
Trial: 1451816
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low dose heparin and AT
Trial: 30636672
Drug: Leech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leech therapy (4-7 leeches, single session)
Trial: 30636672
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (4 weekly sessions, 1 hour each)
Trial: 24329506
Drug: recombinant growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant growth hormone (rhGH) treatment for 2 years
Trial: 21124039
Drug: Weekly irinotecan-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly irinotecan-based therapy
Trial: 21124039
Drug: Biweekly irinotecan-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly irinotecan-based therapy
Trial: 24625508
Drug: First-line therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line therapy
Trial: 16343039
Drug: Fenofibrate +
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate + 10 mg folate
Trial: 16343039
Drug: Fluvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (80 mg)
Trial: 10904122
Drug: Total Sleep
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Sleep Deprivation (TSD) + Light Therapy (150 or 2500 lux)
Trial: 10904122
Drug: Ongoing Lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing Lithium Treatment
Trial: 10904122
Drug: TSD +
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TSD + Light Therapy
Trial: 1735865
Drug: Heparin surface
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin surface modified intraocular lenses
Trial: 1735865
Drug: Control intraocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control intraocular lenses (PMMA without heparin)
Trial: 31205265
Drug: Exercise programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise programme (thrice weekly, supervised exercise on a static bike for six weeks)
Trial: 22985567
Drug: Super Lizer
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Super Lizer group (daily linearly polarized near-infrared irradiation)
Trial: 22985567
Drug: S+P group
RxNorm normalized name: P & S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S+P group (daily Super Lizer and aerothermotherapy)
Trial: 22985567
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (drug therapy and shoulder exercise)
Trial: 18353503
Drug: IV ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ondansetron (0.15 mg/kg; maximum 4 mg)
Trial: 9696240
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication or other types of analgesics
Trial: 2672485
Drug: Doxapram (variable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram (variable rate infusion)
Trial: 26860434
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group), duration 6 weeks.
Trial: 24692480
Drug: Early goal‐directed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early goal‐directed fluid therapy (EGDT) guided by preload volume and cardiac output monitored by transpulmonary thermodilution
Trial: 24692480
Drug: Standard less‐invasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard less‐invasive hemodynamic therapy guided by fluid balance or central venous pressure
Trial: 23155313
Drug: Intraderal route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraderal route (ID) with recombinant hepatitis B vaccine (Engerix B) 2 μg
Trial: 23155313
Drug: Intramuscular route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular route (IM) with recombinant hepatitis B vaccine (Engerix B) 10 μg
Trial: 19330600
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with telmisartan 40 mg/day and hydrochlorothiazide (HCTZ) 12.5 mg/day (T + H, n = 32)
Trial: 19330600
Drug: No change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No change in current drug regimen (CTL, n = 32)
Trial: 17890789
Drug: Mild diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild diuretic treatment in addition to standard treatment for acute COPD exacerbation (group 1A)
Trial: 17890789
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for acute COPD exacerbation (group 1B)
Trial: 8200888
Drug: Electrical capacitive
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrical capacitive coupling treatment
Trial: 12683477
Drug: Abbreviated cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated cognitive‐behavioral insomnia therapy (ACBT)
Trial: 8875723
Drug: 6-month chemotherapy
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month chemotherapy (streptomycin, rifampicin, isoniazid)
Trial: 8875723
Drug: 9-month chemotherapy
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-month chemotherapy (streptomycin, rifampicin, isoniazid)
Trial: 8875723
Drug: 18-month chemotherapy
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18-month chemotherapy (streptomycin, sodium para-aminosalicylic acid, isoniazid)
Trial: 8875723
Drug: All chemotherapy
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All chemotherapy regimens (6-month, 9-month, 18-month)
Trial: 7933184
Drug: Maximal electrical
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal electrical sphincter stimulation (30 minutes twice daily for 12 days)
Trial: 2853406
Drug: Diuretic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic and placebo (combined control group)
Trial: 28043937
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg, once daily)
Trial: 22130488
Drug: Enoxaparin followed
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin followed by idrabiotaparinux (5-10 days' enoxaparin 1.0 mg/kg twice daily followed by subcutaneous idrabiotaparinux starting dose 3.0 mg)
Trial: 22130488
Drug: Enoxaparin plus
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin plus warfarin (adjusted-dose warfarin with target INR 2.0-3.0)
Trial: 18478934
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with Shenqi-fuzheng injection
Trial: 16335682
Drug: EP treatment
RxNorm normalized name: Clearasil Rapid Rescue Deep Treatment 2% Topical Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP treatment with 2mg of estradiol (E2) for 5 years
Trial: 16335682
Drug: EP treatment
RxNorm normalized name: Clearasil Rapid Rescue Deep Treatment 2% Topical Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP treatment with 2mg of estradiol (E2) started before age 15
Trial: 16335682
Drug: EP treatment
RxNorm normalized name: Clearasil Rapid Rescue Deep Treatment 2% Topical Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP treatment with 2mg of estradiol (E2) started after age 20
Trial: 9685472
Drug: Vaccine Information
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine Information Statement (VIS) only
Trial: 8062601
Drug: 50/50 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/50 insulin mixture
Trial: 8062601
Drug: 70/30 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70/30 insulin mixture
Trial: 30054099
Drug: Chlorhexidine (CHX)
RxNorm normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (CHX) group (2-visit treatment)